Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,690 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,690 Papers indexed
371 Papers AI scored
37,690 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37690 results
B
AI -
Base 70.0
Rank 70.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.0/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 40.0; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 70.0
Rank 70.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
Milestone events in recessive dystrophic epidermolysis bullosa: findings of the PEBLES study.
PMID 39874247 Published: 2025-05-23 Ingested: 2026-08-02 12:04 AM Clinical and experimental dermatology
AI -
Base 70.0
Rank 70.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 70.0
Rank 70.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
Cell type transcriptional identities are maintained in cultured ex vivo human brain tissue.
PMID 39763930 Published: 2024-12-20 Ingested: 2026-08-02 12:03 AM bioRxiv : the preprint server for biology
AI -
Base 70.0
Rank 70.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
Nanopore sequencing as a cutting-edge technology for medulloblastoma classification.
PMID 39731757 Published: 2025-06-21 Ingested: 2026-08-02 12:04 AM Neuro-oncology
AI -
Base 70.0
Rank 70.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.0/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 10.0; sample size: 100.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 70.0
Rank 70.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 70.0/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 20.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 583 of 3141
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic